The cost-effectiveness of initiating ranibizumab therapy in eyes with neovascular AMD with good vision: an economic model using real-world outcomes

OBJECTIVES: To evaluate the cost-effectiveness of immediate treatment with ranibizumab in patients with neovascular age-related macular degeneration (nAMD) with good (better than 6/12) starting visual acuity compared with current UK clinical guidance of waiting until vision falls below 6/12 to begin...

Descripción completa

Detalles Bibliográficos
Autores principales: Butt, Thomas, Lee, Aaron, Lee, Cecilia, Tufail, Adnan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2015
Materias:
Health Economics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4431059/
https://www.ncbi.nlm.nih.gov/pubmed/25943370
http://dx.doi.org/10.1136/bmjopen-2014-006535

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4431059/
https://www.ncbi.nlm.nih.gov/pubmed/25943370
http://dx.doi.org/10.1136/bmjopen-2014-006535

Ejemplares similares